The 7 major myocardial infarction markets reached a value of US$ 1.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.4 Billion by 2034, exhibiting a growth rate (CAGR) of 4.94% during 2024-2034.
Report Attribute
|
Key Statistics
|
---|---|
Base Year |
2023
|
Forecast Years | 2024-2034 |
Historical Years |
2018-2023
|
Market Size in 2023
|
US$ 1.4 Billion |
Market Forecast in 2034
|
US$ 2.4 Billion |
Market Growth Rate (2024-2034)
|
4.94% |
The myocardial infarction market has been comprehensively analyzed in IMARC's new report titled "Myocardial Infarction Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Myocardial infarction, also known as a heart attack, is a life-threatening condition that develops when blood flow to the heart muscle is blocked, leading to tissue damage. The most prominent symptom is severe and persistent chest pain or discomfort that may spread to the arms, neck, jaw, or back. This pain is often accompanied by shortness of breath, sweating, nausea, lightheadedness, and an overwhelming sense of anxiety. Some patients may also experience unusual fatigue, heart palpitations, a feeling of indigestion, etc. The diagnosis of myocardial infarction involves a combination of medical history evaluation, physical examination, and diagnostic tests. The healthcare provider will inquire about the patient's symptoms, risk factors, and medical history. During the physical exam, they may monitor heart and lung conditions, check blood pressure, and assess overall signs of distress. Various diagnostic procedures, such as an electrocardiogram (ECG), blood tests, imaging techniques like echocardiography or coronary angiography, etc., are also performed to confirm the diagnosis. These tests help to identify abnormal changes in the heart's electrical activity, detect the presence of certain enzymes released during a heart attack, and visualize the blood flow to the heart.
The increasing cases of coronary artery diseases in which plaque builds up on the inner walls of the arteries and reduces blood flow to the heart muscle are primarily driving the myocardial infarction market. Furthermore, the rising prevalence of various associated risk factors, including high cholesterol levels, excessive alcohol consumption, smoking, lack of physical activity, etc., is acting as another significant growth-inducing factor. Additionally, the emerging popularity of beta-blockers, such as metoprolol, bisoprolol, carvedilol, etc., since they decrease the workload on the heart by slowing the heart rate and lowering blood pressure, thereby promoting healing and reducing the likelihood of future heart attacks, is also creating a positive outlook for the market. Moreover, the increasing utilization of radial access surgery on account of its several associated benefits, including a lower risk of access-site complications, better patient comfort, early mobilization, etc., is further augmenting the market growth. Apart from this, the escalating demand for drug-eluting stents, which have drastically reduced the incidence of restenosis and enhanced the effectiveness of stent placement, is expected to drive the myocardial infarction market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the myocardial infarction market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for myocardial infarction and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the myocardial infarction market in any manner.
Lovenox refers to a low molecular weight heparin used to treat STEMI managed either medically or with subsequent percutaneous coronary intervention. The recommended Lovenox dose is a single IV bolus of 30 mg plus a 1 mg/kg SC dose, followed by 1 mg/kg delivered SC every 12 hours.
Tenecteplase biosimilar (GNR-060) is under development by Generium for the treatment of myocardial infarction. The drug is administered through an intravenous bolus route.
Dutogliptin tartrate (REC-01) is under development for the treatment of acute and post-myocardial infarction. The therapeutic candidate is made as a solution and delivered via subcutaneous injection. The medication candidate is a DPP-IV inhibitor that is also used in conjunction with G-CSF.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current myocardial infarction marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Lovenox (Enoxaparin sodium) | Sanofi |
Retavase (Reteplase) | Chiesi USA, Inc |
Repatha (Evolocumab) | Amgen |
TNKase (Tenecteplase) | Genentech |
Plavix (Clopidogrel) | Sanofi |
Empagliflozin | Boehringer Ingelheim/Eli Lilly and Company |
GNR-060 | GENERIUM Pharmaceuticals |
FDY-5301 | Faraday Pharmaceuticals |
Dutogliptin Tartrate | Recardio |
Zalunfiban | Celecor Therapeutics |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Myocardial Infarction: Current Treatment Scenario, Marketed Drugs and Emerging Therapies